InBrain Neuroelectronics has secured a $4.5 million (€4 million) grant from Spain’s PERTE Chip Program to accelerate its development of graphene-based brain-computer interface (BCI) technology.
Key Highlights:
- The Barcelona-based startup aims to use intelligent computing and graphene materials to decode and modulate brain activity in real time.
- The company’s BCI platform delivers ultra-high signal resolution using ML-powered software to enable adaptive neuromodulation therapy.
- Future applications include treatment for Parkinson’s, stroke recovery, epilepsy, and neuropsychiatric conditions.
- InBrain previously earned FDA Breakthrough Device designation and raised $50M in Series B funding in 2023.
CEO Carolina Aguilar said the funding supports InBrain’s mission to pioneer precision neurotechnology while boosting Spain’s position in deep tech healthcare innovation.
Follow MEDWIRE.AI for the latest in neurotech and BCI advancements.
